Improvement effect of Shegan Mahuang Decoction on rats with cold-induced asthma based on TRPV1/NRF-1/mtTFA pathway.
10.19540/j.cnki.cjcmm.20230831.403
- Author:
Qiu-Hui LI
1
;
Xiao-Xiao SHAN
2
;
Xiao-Ying LIU
1
;
Wei-Dong YE
1
;
Ya-Mei YUAN
1
;
Xun-Yan YIN
1
;
Xiang-Ming FANG
1
Author Information
1. School of Traditional Chinese Medicine, Anhui University of Chinese Medicine Hefei 230012, China.
2. School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China.
- Publication Type:Journal Article
- Keywords:
Shegan Mahuang Decoction;
airway inflammation;
airway remodeling;
cold-induced asthma;
transient receptor potential vanilloid subfamily member 1(TRPV1)
- MeSH:
Rats;
Male;
Animals;
Mice;
Interleukin-4/metabolism*;
Vascular Endothelial Growth Factor A/metabolism*;
Rats, Sprague-Dawley;
Asthma/genetics*;
Lung;
Bronchoalveolar Lavage Fluid;
RNA, Messenger/metabolism*;
Collagen/metabolism*;
Mucins/therapeutic use*;
Ovalbumin;
Disease Models, Animal;
Mice, Inbred BALB C;
TRPV Cation Channels/metabolism*;
Drugs, Chinese Herbal
- From:
China Journal of Chinese Materia Medica
2023;48(23):6414-6422
- CountryChina
- Language:Chinese
-
Abstract:
This study investigated the therapeutic effect of Shegan Mahuang Decoction(SGMHD) on cold-induced asthma in rats and explored its underlying mechanism. Seventy-two healthy male SD rats of specific pathogen free(SPF) grade were randomly divided into a blank group, a model group, a positive control group(dexamethasone, 0.4 mg·kg~(-1)), and low-, medium-, and high-dose SGMHD groups(3.2, 6.4, and 12.8 g·kg~(-1)). The blank group received saline, while the other groups were sensitized by intraperitoneal injection of ovalbumin(OVA) solution. Subsequently, the rats were placed in a cold chamber adjustable to 0-2 ℃, and OVA solution was ultrasonically nebulized to induce cold-induced asthma in rats. After three weeks of treatment, the general behaviors of rats were observed. Hematoxylin-eosin(HE) staining was used to evaluate pathological changes in lung tissues, periodic acid-Schiff(PAS) staining assessed mucin changes, and Masson staining was performed to examine collagen deposition. Enzyme-linked immunosorbent assay(ELISA) was used to measure the levels of the inflammatory factors interleukin-4(IL-4) and vascular endothelial growth factor(VEGF) in serum and bronchoalveolar lavage fluid(BALF). Real-time quantitative polymerase chain reaction(RT-PCR) was employed to assess the mRNA expression levels of transient receptor potential vanilloid subfamily member 1(TRPV1), nuclear respiratory factor 1(NRF-1), and mitochondrial transcription factor A(mtTFA) in lung tissues. Western blot was used to measure the protein expression levels of TRPV1, NRF-1, and mtTFA in lung tissues. Compared with the blank group, the model group exhibited signs of rapid respiration, increased frequency of defecation with looser stools, and disheveled and dull fur. Pathological results showed significant infiltration of inflammatory cells in lung tissues, narrowing of bronchial lumens, increased mucin secretion, and enhanced collagen deposition in the model group. Additionally, the levels of IL-4 and VEGF in serum and BALF were significantly elevated, and the mRNA and protein expression levels of TRPV1, NRF-1, and mtTFA in lung tissues were significantly increased. Compared with the model group, SGMHD improved the behaviors of rats, alleviated pathological changes in lung tissues, mucin production, and collagen deposition, significantly decreased the levels of IL-4 and VEGF in serum and BALF, and reduced the mRNA expression levels of TRPV1, NRF-1, and mtTFA in lung tissues, with the medium-dose SGMHD group showing the most significant effect. Moreover, the protein expression levels of TRPV1, NRF-1, and mtTFA in lung tissues were also reduced, with the medium-dose SGMHD group exhibiting the most significant effect. In conclusion, this study demonstrates that SGMHD can alleviate airway inflammation and inhibit airway remodeling in cold-induced asthma rats. These effects may be associated with the modulation of the TRPV1/NRF-1/mtTFA signaling pathway.
